Vancouver, British Columbia--(Newsfile Corp. - May 10, 2023) - Defence Therapeutics Inc. (CSE: DTC) (OTC Pink: DTCFF) - Defence Therapeutics is a Canadian biotech company that develops immune-related cancer therapies with proprietary technology. With three clinical trials scheduled by year-end, the company offers growth potential for investors. Defence is seeking to license its technology to enhance other companies' products in the pharmaceutical industry.
Cannot view this video? Visit:
https://www.b-tv.com/post/cse-dtc-investor-alert-defence-therapeutics-developing-immune-related-therapies-for-cancer-treatment-btv-30sec
Defence Therapeutics Inc. (CSE: DTC) (OTC Pink: DTCFF)
https://defencetherapeutics.com/
About BTV:
BTV-Business Television is Canada's longest running business show. With Hosts Taylor Thoen and Jessica Katrichak, BTV features emerging companies across the country to bring viewers investment opportunities. BTV also produces News Alerts and branding/ awareness spots for issuers broadcast on BNN Bloomberg, Fox Business News, Bloomberg TV US and Bloomberg Terminals. www.b-tv.com
BTV - Business Television/CEO Clips Contact: Trina Schlingmann (604) 664-7401 x 5 trina@b-tv.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/165568
